Abstract:The active form of vitamin D3, 1,25-dihydroxyvitamin D3, is a major regulator of bone and calcium homeostasis. In addition, this hormone also inhibits the proliferation and stimulates the differentiation of normal as well as malignant cells. Supraphysiological doses of 1,25-dihydroxyvitamin D3 are required to reduce cancer cell proliferation. However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin D3 have been synthesized by the introduction of chemical modifications in the A-ring, central CD-ring region or side chain of 1,25-dihydroxyvitamin D3 in the hope to find molecules with a clear dissociation between the beneficial antiproliferative effects and adverse calcemic side effects. One example of such an analog with a good dissociation ratio is calcipotriol (Daivonex®), which is clinically used to treat the hyperproliferative skin disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used in the clinic for the treatment of cancer although several analogs have been shown to be potent drugs in animal models of cancer. Transcriptomics studies as well as in vitro cell biological experiments unraveled basic mechanisms involved in the antineoplastic effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D3 and analogs act in a cell type- and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 toward S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of tumor cells together with effects on angiogenesis and inflammation have been implicated in the pleiotropic effects of 1,25-dihydroxyvitamin D3 and its analogs. In this review we will give an overview of the action of vitamin D analogs in tumor cells and look forward how these compounds could be introduced in the clinical practice.

Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

Investigation of 20S-Hydroxyvitamin D3 Analogs and Their 1Α-Oh Derivatives As Potent Vitamin D Receptor Agonists with Anti-Inflammatory Activities

Vitamin D analogs: Therapeutic applications and mechanisms for selectivity

The future of vitamin D analogs

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Chemical synthesis, biological activities and action on nuclear receptors of 20S(OH)D3, 20S,25(OH)2D3, 20S,23S(OH)2D3 and 20S,23R(OH)2D3

Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Vitamin D Analogs: Mechanism of Action and Therapeutic Applications

New vitamin D analogs as potential therapeutics in melanoma

Promise of vitamin D analogues in the treatment of hyperproliferative conditions

Current progress in using vitamin D and its analogs for cancer prevention and treatment

Chemical Synthesis and Biological Activities of 20S,24s/r-Dihydroxyvitamin D3 Epimers and Their 1Α-Hydroxyl Derivatives

Vitamin D Analogs in Cutaneous Malignancies

4-Hydroxy-1α,25-Dihydroxyvitamin D3: Synthesis and Structure–Function Study

Design, synthesis, and biological activity of D-bishomo-1α,25-dihydroxyvitamin D 3 analogs and their crystal structures with the vitamin D nuclear receptor

Synthesis and Biological Evaluation of Vitamin D3 Metabolite 20S,23s-Dihydroxyvitamin D3 and Its 23r Epimer

New analogs of vitamin D3

Vitamin D and its analogs as anticancer and anti-inflammatory agents

Biological Effects of CYP11A1-Derived Vitamin D and Lumisterol Metabolites in the Skin

In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland.

Mechanism of Action of Newly Developed Vitamin D Analogue